dc.contributor.author | Hacıoğlu, Muhammet Bekir | |
dc.contributor.author | Köstek, Osman | |
dc.contributor.author | Karabulut, Senem | |
dc.contributor.author | Taştekin, Didem | |
dc.contributor.author | Sezgin Göksu, Sema | |
dc.contributor.author | Alandağ, Celal | |
dc.contributor.author | Akagündüz, Baran | |
dc.contributor.author | Bilgetekin, İrem | |
dc.contributor.author | Caner, Burcu | |
dc.contributor.author | Şahin, Ahmet Bilgehan | |
dc.contributor.author | Yıldız, Birol | |
dc.contributor.author | Köse, Fatih | |
dc.contributor.author | Kaplan, Muhammet Ali | |
dc.contributor.author | Gülmez, Ahmet | |
dc.contributor.author | Doğan, Ender | |
dc.contributor.author | Güven, Deniz Can | |
dc.contributor.author | Gürbüz, Mustafa | |
dc.contributor.author | Ergun, Yakup | |
dc.contributor.author | Karaağaç, Mustafa | |
dc.contributor.author | Demiray, Atike Gökçen | |
dc.contributor.author | Türker, Sema | |
dc.contributor.author | Sakalar, Teoman | |
dc.contributor.author | Özkul, Özlem | |
dc.contributor.author | Akın Telli, Tuğba | |
dc.contributor.author | Şahin, Süleyman | |
dc.contributor.author | Kılıçkap, Saadettin | |
dc.contributor.author | Bilici, Ahmet | |
dc.contributor.author | Erdoğan, Bülent | |
dc.contributor.author | Çiçin, İrfan | |
dc.date.accessioned | 2020-10-16T10:14:30Z | |
dc.date.available | 2020-10-16T10:14:30Z | |
dc.date.issued | 2020 | en_US |
dc.identifier.citation | Hacıoğlu, M. B., Köstek, O., Karabulut, S., Taştekin, D., Sezgin Göksu, S., Alandağ, C. ... Çiçin, İ. (2020). Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey. Journal of B.U.ON., 25(4), 1897-1903. | en_US |
dc.identifier.issn | 1107-0625 | |
dc.identifier.issn | 2241-6293 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/5929 | |
dc.description.abstract | Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting.Methods: In this retrospective and multicenter study, advanced HCC patients not eligible for local therapies, who received a secondor third-line regorafenib therapy after progression on the first-line sorafenib or sequential therapy with chemotherapy (CT) followed by sorafenib, were included.Results: In the first-line setting, 28 (28.9%) patients received CT and 69 (71.1%) patients received sorafenib. There were 24 (24.7%) patients who were intolerant to sorafenib. Disease control rate (DCR) was 53.6% for all patients treated with regorafenib, 62.3% in patients who received regorafenib in the second-line, and 32.1% for those receiving regorafenib in the third-line (p=0.007). Median progression-free survival (PFS) and overall survival (OS) were 5.6 (range; 4.3-6.9) and 8.8 (range, 6.3-11.3) months for all patients treated with regorafenib vs. 7.1 months and 10.3 months for patients who received regorafenib in the second-line vs. 5.1 and 8.7 months for patients who received regorafenib in the third-line, respectively; however, there was no statistically significant difference (p(PFS)=0.22 and p(OS)=0.85).Conclusion: Although receiving CT as a first-line therapy in advanced HCC patients did not affect the survival rates of subsequent regorafenib therapy, it might diminish the DCR of regorafenib. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Imprimatur Publication | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Hepatocellular Carcinoma | en_US |
dc.subject | Regorafenib | en_US |
dc.subject | Disease Control Rate | en_US |
dc.subject | Overall Survival | en_US |
dc.subject | Chemotherapy | en_US |
dc.subject | Anti-VEGF Therapy | en_US |
dc.title | Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Journal of B.U.ON. | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.identifier.volume | 25 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 1897 | en_US |
dc.identifier.endpage | 1903 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.identifier.scopusquality | Q3 | en_US |